Home/Filings/4/0001209191-18-040507
4//SEC Filing

Michelon Francois Roger 4

Accession 0001209191-18-040507

CIK 0001681682other

Filed

Jul 1, 8:00 PM ET

Accepted

Jul 2, 7:33 PM ET

Size

9.3 KB

Accession

0001209191-18-040507

Insider Transaction Report

Form 4
Period: 2018-06-28
Michelon Francois Roger
DirectorChief Executive Officer
Transactions
  • Award

    Convertible Promissory Note

    2018-06-28$10000.00/sh
    Exp: 2018-12-31Common Stock (4,961 underlying)
  • Award

    Warrants

    2018-06-28+2,4802,480 total
    Exercise: $2.52From: 2018-12-28Exp: 2021-06-28Common Stock (2,480 underlying)
Footnotes (4)
  • [F1]The Convertible Promissory Note (the "Note") is convertible into the Issuer's common stock at a conversion price equal to the lesser of (a) the lowest per share price at which common stock is sold by the Issuer in a sale resulting in aggregate gross cash proceeds of at least $7.0 million (a "Qualified Financing"), less a discount of 20%, or (b) $2.016, but in any event no less than a conversion price floor of $1.40, which conversion price is subject to adjustment in certain circumstances in accordance with the terms of the Note.
  • [F2]The principal amount of the Note will automatically convert into shares of the Issuer's common stock (i) upon the consummation of a Qualified Financing or (ii) if the holders of a majority of the aggregate principal amount of outstanding Convertible Promissory Notes elect to convert such notes at any time until three days prior to a Qualified Financing. Additionally, the reporting person is entitled to convert the principal amount of the Note into common stock (i) at any time until three days prior to the consummation of a Qualified Financing or (ii) if a material Event of Default (as defined in the Note) shall have occurred and be continuing. In each case, conversion is subject to the terms and provisions of the Note.
  • [F3]The number of shares of common stock shown in Column 7 assumes a conversion price of $2.016, which is subject to adjustment in certain circumstances (see Footnote 1).
  • [F4]The Warrants were issued for no additional consideration in connection with the offer and sale of the Note.

Issuer

ENDRA Life Sciences Inc.

CIK 0001681682

Entity typeother

Related Parties

1
  • filerCIK 0001691470

Filing Metadata

Form type
4
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 7:33 PM ET
Size
9.3 KB